Clinical trial · Interventional
Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults
Treatment of BCR-ABL Negative ALL in Adults According to MRD and Genetics
NCT04179929CI-TRIAL-00056617recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
After consolidation therapy adult patients (≥18 yr) with Ph-negative ALL will be treated with continuation chemotherapy or allogeneic hematopoietic stem cell transplantation (alloHSCT) according to both measurable residual disease (MRD) and results of genetic study performed at baseline.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| allogeneic HSCT | Procedure | — | UNRESOLVED |
| Pediatric-type of chemotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- CHEMOTHERAPY
- description
- Pediatric-type of chemotherapy
- interventionNames
- Drug: Pediatric-type of chemotherapy
- type
- OTHER
- label
- allogeneic HSCT
- description
- allogeneic HSCT
- interventionNames
- Procedure: allogeneic HSCT
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 3 years
- description
- Time from diagnosis to death or last follow-up
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Patients 18-60 yr with de novo Ph-neg ALL * Eastern Cooperative Oncology Group (ECOG) 0-2 (or \>2 if due to ALL) * Informed consent Exclusion Criteria: * Mature B-ALL, Ph+ ALL or blast crisis of chronic myeloid leukemia (CML), ALL of ambiguous lineage * ECOG \>2 not due to ALL * Impaired cardiac, respiratory, hepatic or renal function not due to ALL * Pregnancy * HIV positivity * Severe psychiatric disease * Negative to sign informed consent.
References
Publications (1)
- DERIVEDRibera JM, Torrent A, Morgades M, Barrena S, Ribera J, Genesca E, Gonzalez-Campos J, Martinez-Cibrian N, Montesinos P, Hernandez Sanchez A, Barba P, Zapico E Sr, Sanchez R, Novo A, Sitges M, Maluquer Artigal C, Such E, Botella C, Queipo de Llano MP, Cabrero M, Vicent A, Lopez de Ugarriza P, Tormo M, Gonzalez-Gonzalez BJ, Garcia-Cadenas I, Rodriguez-Medina C, Martinez Sanchez P, Bermudez A, Gomez-Centurion I, Herrero-Garcia M, Ciudad J, Navas-Acosta J, Hermosin L, Serrano J, Raposo-Puglia JA, Solan L, Roldan-Galiacho V, de Laiglesia A, Gomez-Perez L, Sole-Rodriguez M, Casado MS Sr, Llorente Gonzalez L, Barrios Decoud D, Vall-Llovera F, Algarra JL, Amador L, Garcia-Boyero R, Cladera A, Bergua Burgues JM, Calasanz MJJ, Granada I, Feliu E, Hernandez-Rivas JM, Orfao A. Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood. 2026 May 4:blood.2025032645. doi: 10.1182/blood.2025032645. Online ahead of print. PMID 42081455